Clinical Trials · NCT00085969
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 99
- Start date
- Sep 2003
- Locations
- 23 sites, United States
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28